CANNAINVESTOR Magazine June 2016 - Page 52

Ticker Symbol (OTCQB) “MYDX” Fiscal Year Recent price Market Cap Insider Ownership Shares Out (May 17, 2016) MyDx, In and tec c. (OTCQB: MYD h X duces a nology compa ) is a science ny that nd mark prooperate ets the fi d ical ana , multi-use han rst battery ly d ed MyD zer for consum held chemx™ (My e Diagno rs. Its patentline is co stic) pro m p r is ed du that con nects via of the MyDx de ct phone a vice B lu etoo p effect o p to analyze th th to a smart f e and inh what consume chemical ale (see rs eat, d : www.c r cdxshop ink ). m/ MyDx e x in 2016 pects to reach . The My p Dx analy rofitability for $699 z a n (analyze d includes th er retails r and se e hardw app and nsor), sm are It is mult one-time dispo art phone s change i-use and hous able inserts. es inter able sen sors for plicatio n d By conn s (cannabis, wa ifferent apt e smartph cting to its An er, food, air). droid or one My iOS crowd-s Dx app, o it US sales urced cloud-b leverages a a first ma are expected to sed database. jor distr ibution jump as its effect in deal tak t h e curr e al sales are dive ent quarter. Glo s rse and estimat es. exceedin bg Dec. 31 $0.18 $4 million 47% 22.2M The Ana lyz starting er has a blend ed gros at abou s t 50% a scale wit nd is ex margin h highe pected r volum is now p to es th reparing to manu e Company MyDx A nalyzer fa c ture. Th requires “sample e one in and pro serts,” that are p -time use vid ric with gro e a recurring re ed at $1.29 venue s ss marg tream ins of ap Additio pro nall revenue y, the Compan ximately 80%. y genera on prem tes ium wa ancillary rranties sales. and oth er The San Diego-b ased Co its first p mpany roduct s lau ensor, C 2015 to annaDx nched address TM, in la the exp the can te losive g nab rowth in ers to aff is market and enable ordably consum identify compos the che ition of Goals an mical cannab MyDx H care. A J d Ca is at the une 201 i g •U In h n p creasing talysts for Expo l iq o i 5 int of g ue, Nex of the A study in h t s n Earning t-Genera merican the Jou s Power entially tion Han rnal Medica 75 edib in clude: l d A le canna -held Te 1) Cann bis prod ssociation of chaDX: Th 83% of ucts sold e them m m •A U S canna arket is ddresse nology islabele MyDx a b forecast s Multid the TH found lso has billion d million to reach is testing C th b c o o re y $ ll comme n 800 to $ 2 a e te r 0 n 2 G n e 0 lo t. w bal Marrcializati sensors 900 on in pesticid 2 ) M es in foo pipeline for an its ajor Nan k e ts a d, chem olux Te toxins in bution d •First-M icals in w lyzing the air. eal (targ ch - CannaDx over Ad ater, an •Unrivall dis v ets grow v a a n d lued at ed Com tage ers) sign tri$4M+ petitive ed Q2 Advanta ges, Ma 3) Upgra rket ded ma Leaders •Valuab nufactu c hain h ip le, Grow ring and ing, Inte supply llectual Propert 4 ) L a u y nch •Patente Portfoli differen three new sens d, IP, Ere o t, multio cts High billion d rs that address markets Barriers ollar glo to Entry bal •Veteran Industry 5 ) M S a te nageme ep reve •Solid G nt Team nue ram ross Ma p startin rgins th g Q3-16 at Scale 6) Num erous U with Vo S States lume atives to have ba le llot initipot in N galize medical or recre ovembe ational r 7) Led b Phil Sugarman, VP Investor Relations yC Pfizer Sc EO Daniel Yazb (818) 280-6800 e ientist a nd Mark ck, former Panason et Deve ic. loper to This document contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this document that are not statements of historical fact may be considered to be forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at CANNAINVESTOR Magazine